what was the first digital currency- Top Reviews

Nippon Steel's share price rose by 1.2% shortly after the opening on Wednesday, and it is basically flat at present. In the news, US President Biden plans to formally prevent Nippon Steel from acquiring American steel companies for $14.1 billion. American steel stocks plunged overnight, once falling by 22%, and finally closed down by 9.7%.Guotai Junan's annual strategy for innovative drugs in 2025: innovative pharmaceutical companies have accelerated into the harvest period, and the valuation has been at a historical low in the past five years. Guotai Junan said that the centralized purchasing policy has become stable, mature and normalized, and the marginal impact has weakened. Innovative drugs have gained policy inclination in the medical insurance negotiation. In the past two years, the policy has continued to promote pharmaceutical innovation, and the top-level design and local supporting chain support the development of innovative drugs. Commercial insurance is expected to bring new growth momentum to China's pharmaceutical market, and the overall industry trend is upward. At present, the trend of innovative drug industry is improving, the supply continues to accelerate, and a number of domestic innovative drugs are approved soon, which is expected to drive a new round of heavy volume. At the same time, the commercialization has achieved remarkable results and has occupied a dominant position in some sub-sectors. Pharma's performance continued to differentiate, and innovative drugs and just-needed drugs performed well. Biotech commercialization continues to increase, per capita yield continues to increase, the node of turning losses is approaching, and innovation ushers in the harvest period. Horizontal comparison: compared with overseas peers, the overall valuation of domestic innovative pharmaceutical companies is in a historically low range; Vertical comparison: the valuation of SW- pharmaceutical biology and SW- chemical preparations is at a historical low in the past five years, and it is expected that the valuation of subsequent sectors will pick up.13 shares registered today, Hengxuan Technology, Xiamen Bank and Deshi shares have the strongest dividends. According to the statistics of the equity distribution plan of listed companies, 13 A shares registered today. Among them, 13 shares intend to pay dividends. In terms of dividends, 13 stocks paid dividends in date of record on December 11th. Hengxuan Technology, Xiamen Bank and Deshi Co., Ltd. have the strongest dividends, with dividends of 7.60 yuan for every 10 shares, 1.5 yuan and 1.2 yuan respectively. In addition, there are 5 shares that have thrown out dividend payout plans, among which Contemporary Amperex Technology Co., Limited, Taotao Auto Industry and Hite Bio have the strongest dividend payout, with dividends of 12.3 yuan for every 10 shares, 5 yuan and 1.3 yuan respectively.

Desai Siwei and Infineon jointly set up an innovative application center. Recently, the signing and unveiling ceremony of Desai Siwei-Infineon innovative application center and the signing ceremony of the memorandum of cooperation on intelligent driving domain control were held in Huizhou. At present, Desai Siwei and Infineon are relying on the Innovation Application Center to jointly define the MCU chip architecture of the future EEA, test the performance and evaluate the reliability of TC4x MCU devices, so as to provide innovative solutions to customers. In the future, Desai Siwei will join hands with Infineon to carry out joint technical research in two key areas: intelligent driving and cockpit, and accelerate the commercialization of more innovative product technical solutions.CITIC Securities: In 2025, the performance boom cycle of the US Internet sector is expected to continue. According to CITIC Securities Research Report, looking forward to 2025, the macro resilience will continue, and the superimposed GenAI technology will continue to be introduced. The performance boom cycle of the US Internet sector is expected to continue, which is reflected in online advertising, e-commerce, streaming media, local life, financial technology and other sectors. However, the Trump administration's tariff increase & industry regulatory policies, inflation data, AI technology progress, etc. are expected to be continuous disturbance variables and need to be closely watched. At the level of individual stocks, the first-line Internet giants will still be the basic allocation. At the same time, we suggest that investors appropriately increase the allocation of small and medium-sized stocks in the fields of advertising technology and financial technology to enhance portfolio flexibility.Analyst: There may be a RRR cut of 50 basis points to 100 basis points next year. Tan Yiming, chief fixed income analyst of Minsheng Securities, said that there may be a RRR cut of 50 basis points to 100 basis points next year, considering the supply pressure of government bonds, the restoration of credit supply and the provision of long-term stable low-cost funds for financial institutions.

Guotai Junan's annual strategy for innovative drugs in 2025: innovative pharmaceutical companies have accelerated into the harvest period, and the valuation has been at a historical low in the past five years. Guotai Junan said that the centralized purchasing policy has become stable, mature and normalized, and the marginal impact has weakened. Innovative drugs have gained policy inclination in the medical insurance negotiation. In the past two years, the policy has continued to promote pharmaceutical innovation, and the top-level design and local supporting chain support the development of innovative drugs. Commercial insurance is expected to bring new growth momentum to China's pharmaceutical market, and the overall industry trend is upward. At present, the trend of innovative drug industry is improving, the supply continues to accelerate, and a number of domestic innovative drugs are approved soon, which is expected to drive a new round of heavy volume. At the same time, the commercialization has achieved remarkable results and has occupied a dominant position in some sub-sectors. Pharma's performance continued to differentiate, and innovative drugs and just-needed drugs performed well. Biotech commercialization continues to increase, per capita yield continues to increase, the node of turning losses is approaching, and innovation ushers in the harvest period. Horizontal comparison: compared with overseas peers, the overall valuation of domestic innovative pharmaceutical companies is in a historically low range; Vertical comparison: the valuation of SW- pharmaceutical biology and SW- chemical preparations is at a historical low in the past five years, and it is expected that the valuation of subsequent sectors will pick up.After the strike ended, the delivery of Boeing aircraft dropped to 13 in November. On Tuesday, Boeing reported that it delivered 13 commercial jets in November, less than a quarter of the 56 jets delivered to customers 12 months ago. The number of deliveries in October decreased from 14 in October, when most of the company's aircraft production was still in a state of suspension, and 33,000 factory workers went on strike for seven weeks, which ended on November 5. Boeing shares closed up 4.5% on Tuesday. The aircraft manufacturer said that after weeks of methodical preparations, the company restarted the production of the 737 MAX and loaded the new fuselage into the Renton factory in Seattle.NVIDIA's market value evaporated by 660 billion yuan overnight. On December 10th, local time, the three major US stock indexes collectively closed down, with the Dow down 0.35%, the Nasdaq down 0.25% and the S&P 500 index down 0.30%. Among them, NVIDIA fell by 2.69%, and its market value evaporated by 91.593 billion US dollars (about 664.047 billion yuan) overnight.